Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication | ||
|---|---|---|
| All Indications | 400 mg PO BID | No adjustment for renal dysfunction |
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
|
Indication |
Intermittent Hemodialysis |
Continuous Hemodialysis |
|---|---|---|
| All Indications | No data; consider using standard 400 mg PO BID | No data; consider using standard 400 mg PO BID |
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.
Dose increase required when administered with drug metabolizing enzyne inducers.
Restricted to ID or Antimicrobial Stewardship except:
1) Continuation of prior therapy
ZSFG: Non-formulary
References:
Robin K Avery, Sophie Alain, Barbara D Alexander, Emily A Blumberg, Roy F Chemaly, Catherine Cordonnier, Rafael F Duarte, Diana F Florescu, Nassim Kamar, Deepali Kumar, Johan Maertens, Francisco M Marty, Genovefa A Papanicolaou, Fernanda P Silveira, Oliver Witzke, Jingyang Wu, Aimee K Sundberg, Martha Fournier, SOLSTICE Trial Investigators, Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial, Clinical Infectious Diseases, Volume 75, Issue 4, 15 August 2022, Pages 690–701, https://doi.org/10.1093/cid/ciab988